FDA Brief

Warning letters Drugs

FDA warning letter to

Strut Health, LLC dba Strut

LowIssued Feb 20Posted Mar 3Center for Drug Evaluation and Research (CDER)

FDA says Strut Health's website falsely labeled compounded semaglutide and tirzepatide as its own and FDA-approved.

What happened

FDA reviewed Strut's website at https://www.struthealth.com in December 2025 and found it offered compounded semaglutide and tirzepatide drug products. The website labels displayed "Strut" in a way that suggested Strut was the compounder, but FDA says Strut is not the compounder. The website also used claims such as "Generic Zepbound, Mounjaro" that implied the compounded products were FDA-approved.

What FDA found

  1. The website labels showed "Strut" as if Strut made the compounded semaglutide and tirzepatide products, but FDA says Strut is not the compounder.

    FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]; 21 CFR § 201.1(h)(2)
  2. The website called the compounded products "Generic Zepbound, Mounjaro," which suggested FDA approval that the products do not have.

    FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. The website said semaglutide is the active ingredient in brand medications and tirzepatide is the active ingredient in Zepbound and Mounjaro, which implied the compounded products were approved or evaluated for safety and effectiveness.

    FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  4. The compounded semaglutide and tirzepatide products are not FDA-approved, so the website claims were false or misleading.

    FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  5. The falsely labeled or advertised products were introduced or delivered for introduction into interstate commerce.

    FDCA section 301(a) [21 U.S.C. § 331(a)]

What FDA wants

FDA asks Strut to respond in writing within 15 working days describing steps taken to fix the violations, including identifying who makes the compounded products, providing sample labeling, and addressing or removing the misleading website claims.

Who should pay attention

  • telehealth companies selling compounded GLP-1 drugs
  • compounding pharmacies whose products are advertised by other websites
  • marketers that compare compounded drugs to FDA-approved brands

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low